{'fraction_non_alphanumeric': 0.06762295081967214, 'fraction_numerical': 0.05327868852459016, 'mean_word_length': 4.425925925925926, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Effects of bosentan in treatment of pulmonary arterial hypertension: a pilot study of 21 patients].

OBJECTIVE
To investigate the preliminary efficacy and safety of bosentan, a dual endothelin-receptor antagonist, in Chinese pulmonary arterial hypertension (PAH) patients.


METHODS
21 patients with PAH, idiopathic or associated with congenital heart disease or connective-tissue disease received 62.5 mg of bosentan twice daily for 4 weeks, and then 125 mg twice daily for 8 weeks if without serious side effects. At week 12, the patients underwent 6 min walk test, hemodynamic variables examination, right heart catheterization, ultrasound cardiography, and electrocardiography.


RESULTS
The six-minute walking distance 12 weeks after bosentan treatment was 461 m +/- 84 m, significantly longer than that before the therapy (374 m +/- 113 m, P < 0.001). The pulmonary vascular resistance 12 weeks after the bosentan treatment was (1236 +/- 729) dyn x s(-1) x cm(-5), significantly lower than that before [(1,440 +/- 766) dyn x s(-1) x cm(-5), P = 0.007]. The cardiac index 12 weeks after the bosentan treatment was (3.02 +/- 1.71) L x min(-1)xm(2), significantly higher than that before treatment [(2.35 +/- 1.20) L x min(-1)xm(2), P = 0.002]. No patient was withdrawn from this study for safety reason.


CONCLUSION
Improves the exercise capacity and hemodynamic parameters in Chinese PAH patients; bosentan is safe in treating PAH and can be well tolerated.